Compare GEO & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | CNTA |
|---|---|---|
| Founded | 1984 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 3.5B |
| IPO Year | 1996 | 2021 |
| Metric | GEO | CNTA |
|---|---|---|
| Price | $17.33 | $39.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $39.67 | ★ $42.50 |
| AVG Volume (30 Days) | 2.4M | ★ 3.2M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 727.27 | 29.13 |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $2,263,420,000.00 | $15,000,000.00 |
| Revenue This Year | $13.74 | N/A |
| Revenue Next Year | $9.99 | N/A |
| P/E Ratio | $9.24 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $12.51 | $9.60 |
| 52 Week High | $32.09 | $40.26 |
| Indicator | GEO | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 78.06 |
| Support Level | $16.01 | $22.49 |
| Resistance Level | $17.66 | N/A |
| Average True Range (ATR) | 0.75 | 1.66 |
| MACD | 0.13 | 1.11 |
| Stochastic Oscillator | 91.33 | 97.05 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services. The company operates in U.S, Australia and South Africa.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.